MedTrace Logo

Divided Dose of TRAVATAN®

NCT01298687 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2017-05-05

No results posted yet for this study

Summary

The purpose of this study is to compare the incremental dosing of travoprost ophthalmic solution versus once a day dosing of TRAVATAN® in lowering intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Conditions

Interventions

DRUG

Travoprost Ophthalmic Solution, 0.00013%

Cumulative daily dose is below the travoprost ophthalmic solution, 0.004% once daily dose

DRUG

Travoprost Ophthalmic Solution, 0.00033%

Cumulative daily dose equals the travoprost ophthalmic solution, 0.004% once daily dose

DRUG

Travoprost Ophthalmic Solution, 0.001%

Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose

DRUG

Travoprost Ophthalmic Solution, 0.00267%

Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose

DRUG

Travoprost Ophthalmic Solution, 0.004%

DRUG

Travoprost Vehicle

Inactive ingredients used as an active comparator

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Matt Walker, PhD · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2011-04-30
Completion
2011-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01298687 on ClinicalTrials.gov